Abstract:BackgroundThe role of alprostadil on the prevention of contrast-induced nephropathy (CIN) still remains controversial. The purpose of this study was to examine the effects of short-term alprostadil on the incidence of CIN in patients undergoing elective percutaneous coronary intervention (PCI). MethodsA total of 480 patients with coronary heart disease undergoing PCI were enrolled in our study and randomly assigned to two groups. The control group (n=240) was given only hydration therapy and the alprostadil group (n=240) received intravenous administration of 20 ug/day (diluted with 100 ml normal saline) from 0.5 approximate to 1 hr before to 3 days after operation on the basis of hydration. The primary endpoint of the study was the incidence of CIN, which was defined as an increase in SCr concentration44.2 umol/l or 25% above baseline within 48 hr approximate to 72 hr after exposure of contrast media. ResultsThe incidence of CIN was significantly lower in the alprostadil group than that in the control group (6.25% vs 11.67%, P=0.038). Multivariate logistic regression analysis showed that alprostadil was the protective factor of CIN (OR=0.699, 95% CI 0.542-0.902, P=0.006). The benefits against CIN were consistent in prespecified high-risk patients with diabetes mellitus (P=0.003). In addition, we also found that hs-CRP and blood homocysteine values after PCI were significantly lower in the alprostadil group than those in the control group. ConclusionProphylactic administration of alprostadil may prevent against CIN in coronary heart disease patients undergoing elective PCI, particularly in high-risk patients with diabetes mellitus.

Author Correction: Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis

Correction: Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Correction: Corrigendum: Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study

Efficacy of alprostadil for preventing of contrast-induced nephropathy: A meta-analysis

Corrigendum: Impact of Serum Uric Acid Lowering and Contemporary Uric Acid-Lowering Therapies on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Correction To: Early Presence of Anti-Angiogenesis-related Adverse Events As a Potential Biomarker of Antitumor Efficacy in Metastatic Gastric Cancer Patients Treated with Apatinib: a Cohort Study

Correction To: Early Versus Late Initiation of Renal Replacement Therapy Impacts Mortality in Patients with Acute Kidney Injury Post Cardiac Surgery: a Meta-Analysis

Corrigendum: Effectiveness, safety, and treatment pattern of sodium zirconium cyclosilicate in Chinese patients with hyperkalemia: interim analysis from a multicenter, prospective, real-world study (Actualize Study)

Corrigendum: Receptor of advanced glycation end products deficiency attenuates cisplatin-induced acute nephrotoxicity by inhibiting apoptosis, inflammation and restoring fatty acid oxidation

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Correction: Prognostic and Clinicopathological Value of P53 Expression in Renal Cell Carcinoma: a Meta-Analysis

Corrigendum to “Efficacy and Safety of Butorphanol Use in Patient-Controlled Analgesia: A Meta-Analysis”

Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Correction to: The efficacy and safety of menatetrenone in the management of osteoporosis: a systematic review and meta-analysis of randomized controlled trials

Correction to: Efficacy and Safety of Supportive Care Biosimilars Among Cancer Patients: A Systematic Review and Meta‑Analysis

Efficacy of Alprostadil in Preventing Contrast‐induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Multicenter Prospective Randomized Controlled Trial

Efficacy of Alprostadil in Preventing Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis

Corrigendum: The predictive value of pre-operative N-terminal pro-B-type natriuretic peptide in the risk of acute kidney injury after non-cardiac surgery

Author Correction: PHF14: an Innate Inhibitor Against the Progression of Renal Fibrosis Following Folic Acid-Induced Kidney Injury

Author Correction: A Systems Pharmacology Approach to Determine Active Compounds and Action Mechanisms of Xipayi Kuijie'an enema for Treatment of Ulcerative colitis

Author Correction: A Systems Pharmacology Approach to Determine Active Compounds and Action Mechanisms of Xipayi Kuijie’an enema for Treatment of Ulcerative colitis